Geron Corp. Stock
€1.09
Your prediction
Geron Corp. Stock
Pros and Cons of Geron Corp. in the next few years
Pros
Cons
Performance of Geron Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Geron Corp. | 1.070% | 2.400% | -7.128% | -71.563% | -66.368% | -51.472% | -28.204% |
| Krystal Biotech | 1.160% | 1.999% | 8.577% | 0.215% | 7.293% | 110.710% | - |
| Ardelyx Inc. | 5.170% | 20.444% | 11.196% | -6.526% | 5.015% | 242.306% | 16.488% |
| Evolus Inc | -1.750% | 0.000% | 10.891% | -62.162% | -46.667% | -34.503% | 118.239% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Analyzing the financials of Geron Corporation (NASDAQ: GERN) offers a glimpse into a company that is navigating the complex and often turbulent waters of the biotechnology and medical research sector. The fiscal numbers reveal a company that is currently grappling with consistent operating losses, a significant debt load, and an overall negative profitability trajectory. However, there are glimmers of future potential lying on the horizon, particularly thanks to growth in revenue and robust investor interest.
Market Capitalization and Potential Value: With a market capitalization near $2.63 billion, Geron is positioned as a notable player in the biotechnology field. The valuation indicates a certain level of investor confidence, reflecting expectations that the company may successfully bring its offerings to market.
Revenue Growth: The reported quarterly revenue growth of approximately 13.48% year-over-year is a promising sign. Growing revenues are crucial for a biotech firm, as they indicate progress in product development and market acceptance. Even with an overall revenue figure pegged at $520,000 TTM, this growth suggests the company could be positioning itself well against competitors.
Comments
News
Geron (GERN) Q2 Revenue Jumps 5,477%
Geron (NASDAQ:GERN), a biotechnology company focused on therapies for blood disorders, released its second quarter 2025 results on August 6, 2025. The headline news was a sharp acceleration in
Why Geron Stock Crept Higher Today
Shares of commercial-stage biotech Geron (NASDAQ: GERN) couldn't quite surmount the hump of Hump Day. After the company released its latest set of quarterly figures, its stock price wobbled as